2025 Q3 -tulosraportti
83 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
2,96%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 076 533
Myynti
Määrä
2 073 261
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 284 | - | - | ||
| 1 | - | - | ||
| 200 | - | - | ||
| 265 | - | - | ||
| 450 | - | - |
Ylin
391,2VWAP
Alin
379,45VaihtoMäärä
2 039,6 5 326 428
VWAP
Ylin
391,2Alin
379,45VaihtoMäärä
2 039,6 5 326 428
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·21 min sittenThe latest guidance from Novo Nordisk from the Q3 report (5-11 -25) some analysts consider it a conservative statement. Sales growth 8-11 percent operating profit 4-7 percent. Of course, the exchange rate negatively affects Novo in their DKK-reported figures, when USD accounts for over 70 percent of sales) weakens against DKK
·29 min sittenLast week there were rockets and hype about crossing 400, which it eventually did. Now pessimism prevails and "should have sold", "we're going down to 350" etc... One thing I have learned is that when this pessimism prevails around Novo, it is a buy signal. No one knows any more or less than last week. A general meeting at Novo creates panic among several here and everything is again wrong with Novo. Quite a neurotic forum this is. I have written several posts previously about what Novo's pill launch means, the lead on LLY, 7.2mg that will equalize... I hear doctors everywhere saying that the pill is a gamechanger and that Novo probably has the best pill. Patent expiry is exaggerated. It's not just for copycats to copy neither wegovy nor mounjaro with the same result. They will not get the same effect or side effect profiles. They will always be there as a disruptive element in the market, but nevertheless small players. The pills that will dominate the market will be patent protected for a good while ahead and much harder to copy, if not impossible.
·35 min sittenDoes anyone know how far along Novo is with the launch of their pill in the EU? ☺️
·2 t sittenDear friends. If the company can see they cannot meet expectations. Then the company must issue a profit warning. Short answer: there is no fixed timeframe – but there are some clear patterns. Typically, one sees that a profit warning comes: 2–8 weeks before financial reporting, when management can see that expectations cannot be met. As soon as management has “sufficient knowledge” that guidance will not hold – especially for listed companies. They must not wait strategically. Maybe the stock falls, maybe it doesn't. But if you are the type who shits their pants every time a stock rises/falls 5%. Maybe you should consider another hobby. Novo is gold on the street - with a brilliant future ahead. 👌 my five cent
·1 t sittenI believe Novo will fall sharply when Mike presents the expectations for 2026 - I don't think private investors have realized what headwinds mean. But let's just see some numbers instead of all the doomsday theories or how much Novo is worth in the future, that's nothing but guesswork.
·1 t sittenThat's not how the pharmaceutical industry is traded, but I'll let it be. The problem is the massive uncertainty regarding earnings before patent expiry. Currently, Novo Nordisk is traded with a large risk premium because of this. It goes without saying that X% down compared to market expectation results in an X% lower share price, provided that the risk premium is unchanged. No one knows how conservative the announcement will be. I personally hope that it's a round 0 at constant exchange rates, plus -5% due to a falling dollar exchange rate NB! I own shares in NN. This is neither a buy nor a sell recommendation. Remember due diligence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
83 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
2,96%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 min sittenThe latest guidance from Novo Nordisk from the Q3 report (5-11 -25) some analysts consider it a conservative statement. Sales growth 8-11 percent operating profit 4-7 percent. Of course, the exchange rate negatively affects Novo in their DKK-reported figures, when USD accounts for over 70 percent of sales) weakens against DKK
- ·29 min sittenLast week there were rockets and hype about crossing 400, which it eventually did. Now pessimism prevails and "should have sold", "we're going down to 350" etc... One thing I have learned is that when this pessimism prevails around Novo, it is a buy signal. No one knows any more or less than last week. A general meeting at Novo creates panic among several here and everything is again wrong with Novo. Quite a neurotic forum this is. I have written several posts previously about what Novo's pill launch means, the lead on LLY, 7.2mg that will equalize... I hear doctors everywhere saying that the pill is a gamechanger and that Novo probably has the best pill. Patent expiry is exaggerated. It's not just for copycats to copy neither wegovy nor mounjaro with the same result. They will not get the same effect or side effect profiles. They will always be there as a disruptive element in the market, but nevertheless small players. The pills that will dominate the market will be patent protected for a good while ahead and much harder to copy, if not impossible.
- ·35 min sittenDoes anyone know how far along Novo is with the launch of their pill in the EU? ☺️
- ·2 t sittenDear friends. If the company can see they cannot meet expectations. Then the company must issue a profit warning. Short answer: there is no fixed timeframe – but there are some clear patterns. Typically, one sees that a profit warning comes: 2–8 weeks before financial reporting, when management can see that expectations cannot be met. As soon as management has “sufficient knowledge” that guidance will not hold – especially for listed companies. They must not wait strategically. Maybe the stock falls, maybe it doesn't. But if you are the type who shits their pants every time a stock rises/falls 5%. Maybe you should consider another hobby. Novo is gold on the street - with a brilliant future ahead. 👌 my five cent·1 t sittenI believe Novo will fall sharply when Mike presents the expectations for 2026 - I don't think private investors have realized what headwinds mean. But let's just see some numbers instead of all the doomsday theories or how much Novo is worth in the future, that's nothing but guesswork.·1 t sittenThat's not how the pharmaceutical industry is traded, but I'll let it be. The problem is the massive uncertainty regarding earnings before patent expiry. Currently, Novo Nordisk is traded with a large risk premium because of this. It goes without saying that X% down compared to market expectation results in an X% lower share price, provided that the risk premium is unchanged. No one knows how conservative the announcement will be. I personally hope that it's a round 0 at constant exchange rates, plus -5% due to a falling dollar exchange rate NB! I own shares in NN. This is neither a buy nor a sell recommendation. Remember due diligence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 076 533
Myynti
Määrä
2 073 261
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 284 | - | - | ||
| 1 | - | - | ||
| 200 | - | - | ||
| 265 | - | - | ||
| 450 | - | - |
Ylin
391,2VWAP
Alin
379,45VaihtoMäärä
2 039,6 5 326 428
VWAP
Ylin
391,2Alin
379,45VaihtoMäärä
2 039,6 5 326 428
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
2025 Q3 -tulosraportti
83 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
3,75 DKK/osake
Viimeisin osinko
2,96%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 min sittenThe latest guidance from Novo Nordisk from the Q3 report (5-11 -25) some analysts consider it a conservative statement. Sales growth 8-11 percent operating profit 4-7 percent. Of course, the exchange rate negatively affects Novo in their DKK-reported figures, when USD accounts for over 70 percent of sales) weakens against DKK
- ·29 min sittenLast week there were rockets and hype about crossing 400, which it eventually did. Now pessimism prevails and "should have sold", "we're going down to 350" etc... One thing I have learned is that when this pessimism prevails around Novo, it is a buy signal. No one knows any more or less than last week. A general meeting at Novo creates panic among several here and everything is again wrong with Novo. Quite a neurotic forum this is. I have written several posts previously about what Novo's pill launch means, the lead on LLY, 7.2mg that will equalize... I hear doctors everywhere saying that the pill is a gamechanger and that Novo probably has the best pill. Patent expiry is exaggerated. It's not just for copycats to copy neither wegovy nor mounjaro with the same result. They will not get the same effect or side effect profiles. They will always be there as a disruptive element in the market, but nevertheless small players. The pills that will dominate the market will be patent protected for a good while ahead and much harder to copy, if not impossible.
- ·35 min sittenDoes anyone know how far along Novo is with the launch of their pill in the EU? ☺️
- ·2 t sittenDear friends. If the company can see they cannot meet expectations. Then the company must issue a profit warning. Short answer: there is no fixed timeframe – but there are some clear patterns. Typically, one sees that a profit warning comes: 2–8 weeks before financial reporting, when management can see that expectations cannot be met. As soon as management has “sufficient knowledge” that guidance will not hold – especially for listed companies. They must not wait strategically. Maybe the stock falls, maybe it doesn't. But if you are the type who shits their pants every time a stock rises/falls 5%. Maybe you should consider another hobby. Novo is gold on the street - with a brilliant future ahead. 👌 my five cent·1 t sittenI believe Novo will fall sharply when Mike presents the expectations for 2026 - I don't think private investors have realized what headwinds mean. But let's just see some numbers instead of all the doomsday theories or how much Novo is worth in the future, that's nothing but guesswork.·1 t sittenThat's not how the pharmaceutical industry is traded, but I'll let it be. The problem is the massive uncertainty regarding earnings before patent expiry. Currently, Novo Nordisk is traded with a large risk premium because of this. It goes without saying that X% down compared to market expectation results in an X% lower share price, provided that the risk premium is unchanged. No one knows how conservative the announcement will be. I personally hope that it's a round 0 at constant exchange rates, plus -5% due to a falling dollar exchange rate NB! I own shares in NN. This is neither a buy nor a sell recommendation. Remember due diligence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 076 533
Myynti
Määrä
2 073 261
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 284 | - | - | ||
| 1 | - | - | ||
| 200 | - | - | ||
| 265 | - | - | ||
| 450 | - | - |
Ylin
391,2VWAP
Alin
379,45VaihtoMäärä
2 039,6 5 326 428
VWAP
Ylin
391,2Alin
379,45VaihtoMäärä
2 039,6 5 326 428
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 100 | 100 | 0 | 100 |
| Anonyymi | 5 326 328 | 5 326 328 | 0 | 0 |